- About Us
- Our Work
- Work With MSF
- Public Events
- Press Room
EU-India Free Trade Agreement: Last Chance to Unblock Access to Medicines
AudioA BBC Overview of the Threat to Generics, with an Interview with MSF (beginning at 13:06)
April 26, 2010, Brussels/New York – As the European Commission (EC) and India meet for closed-door negotiations on a Free Trade Agreement (FTA) this week, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) warns this is the last chance to remove provisions that will block access to life-saving medicines for people living in the developing world.
“Neither the Indian Trade Minister nor the EU Trade Commissioner have given a public commitment that the provisions that affect generic competition and access to medicines are off the table,” said Michelle Childs, director of policy and advocacy at MSF’s Campaign for Access to Essential Medicines. “We will continue to fight until they are officially and unequivocally out of the agreement.”
India is the source of 80 percent of the AIDS medicines used in MSF projects. Without quality affordable medicines from Indian sources, it would have been impossible to scale up treatment to the levels seen today and millions of lives would not have been saved.
Through their governments’ contributions to the Global Fund and other international health agencies, European taxpayers pay for programs that can treat far more people, thanks to affordable medicines from India. But MSF and other groups are concerned that the EC is now trading this away. The draft agreement contains several alarming provisions on intellectual property and enforcement—much stricter than anything required under the international trade rules—that threaten the supply of essential medicines from India.
“The right to life and health of people in developing countries is being sacrificed in this deal,” said Loon Gangte, president of the Delhi Network of Positive People (DNP+). “Do not put profits before patients. This trade agreement must not undermine India’s ability to provide people living with HIV/AIDS here and outside India with life-saving medicines in the name of open markets.”
One of the harmful provisions in the FTA is something known as ‘data exclusivity’. If introduced by India, data exclusivity will obligate generic companies wishing to register a medicine to repeat clinical studies. This not only creates huge financial barriers that act as disincentives to generic companies, but also violates medical ethics, as people would be subjected to the risks of clinical studies for something that is already known. Data exclusivity therefore creates a new patent-like barrier to access to medicines and vaccines, even when these products are not protected by a patent.
Also in the draft FTA is a provision that extends the duration of a patent term beyond 20 years. In addition, after multiple incidents of Indian generic medicines being detained while in transit to other developing countries in Latin America, Asia, and Africa, the EU is now seeking to legitimize such measures.